Characterising long term Covid-19: a living systematic review
medrxiv(2021)
摘要
Background While it is now apparent clinical sequelae (often called Long Covid) may persist after acute Covid-19, their nature, frequency, and aetiology are poorly characterised. This study aims to regularly synthesise evidence on Long Covid characteristics, to inform clinical management, rehabilitation, and interventional studies to improve long term outcomes.
Methods A living systematic review. Medline, CINAHL (EBSCO), Global Health (Ovid), WHO Global Research Database on Covid-19, LitCOVID, and Google Scholar were searched up to 17th March 2021. Published studies including at least 100 people with confirmed or clinically suspected Covid-19 at 12 weeks or more post-onset were included. Results were analysed using descriptive statistics and meta-analyses to estimate prevalence with 95% confidence intervals (CIs).
Results Thirty-nine studies were included: 32 cohort, six cross-sectional, and one case-control. Most showed high or moderate risk of bias. None were set in low-income countries, limited studies included children. Studies reported on 10,951 people (48% female) in 12 countries. Most followed-up post hospital discharge (78%, 8520/10951). The longest mean follow-up was 221.7 (SD: 10.9) days post Covid-19 onset. An extensive range of symptoms with wide prevalence was reported, most commonly weakness (41%; 95% CI 25% to 59%), malaise (33%; 95% CI 15% to 57%), fatigue (31%; 95% CI 24% to 39%), concentration impairment (26%; 95% CI 21% to 32%), and breathlessness (25%; 95% CI 18% to 34%). Other frequent symptoms included musculoskeletal, neurological, and psychological. 37% (95% CI 18% to 60%) of people reported reduced quality of life.
Conclusion Long Covid is a complex condition with heterogeneous symptoms. The nature of the studies precludes a precise case definition or evaluation of risk factors. There is an urgent need for prospective, robust, standardised controlled studies into aetiology, risk factors, and biomarkers to characterise Long Covid in different at-risk populations and settings.
Systematic review registration The protocol was prospectively registered on the PROSPERO database (CRD42020211131).
Section 1: What is already known?
Section 2: What are the new findings?
Section 3: What do the new findings imply?
### Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years. JCS declares he is an individual living with long-term symptoms of probably covid-19. All other authors declare no other relationships or activities that could appear to have influenced the submitted work.
### Funding Statement
This work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome [215091/Z/18/Z] and the Bill & Melinda Gates Foundation [OPP1209135]. The results presented have been obtained with the financial support of the EU FP7 project PREPARE (602525).
### Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No ethics approval was needed
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
All data are available on the paper
* ADL
: Activities of daily living
AKI
: Acute kidney injury
COVID-19
: Coronavirus Disease
DCLO
: Diffusion capacity for carbon monoxide
ICU
: Intensive care unit
IQR
: Interquartile Range
ISARIC
: International Severe Acute Respiratory and emerging Infection Consortium
LMIC
: Low-middle income country
LSR
: Living’ systematic review
NICE
: National Institute for Health and Care Excellence
NIHR
: National Institute for Health Research
PTSD
: post traumatic stress disorder
RoB
: Risk of bias
SARS-CoV-2
: Severe Acute Respiratory Syndrome Coronavirus-2
SD
: Standard deviation
VAS
: Visual Analogue Scale
更多查看译文
关键词
systematic review,long term
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要